RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $260
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $259 to $260.
RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $259 to $260.